Publication date: Jun 30, 2026
Patients with hematological malignancies are vulnerable to psychological distress in times of crisis. We evaluated emotional burden, including demographic and clinical factors associated with war-related fears and depression severity, as well as coping strategies, and care continuity during the 2023-2025 war in Israel and compared findings to a prior COVID-19 survey. A national cross-sectional survey was conducted in September 2025 among Hebrew-speaking patients with hematological malignancies. Data included sociodemographic and clinical items, disease management, fears (Likert scales), the Patient Health Questionnaire-9 (PHQ-9), and three open-ended questions analyzed thematically. Results were compared with a similar 2021 COVID-19 survey. Of 836 patients approached, 188 responded (22%). War affected many patients: 45% had a relative recruited to the army, and 2% reported evacuation or a family member injured/killed. Treatment disruptions were limited (8% delays, 7% alternative therapy, one deferred CAR-T). Depression was frequent (mean PHQ-9 was 10. 4 +/- 5. 6), with 49% in moderate-to-severe ranges, significantly higher than during COVID-19 (9. 2 +/- 5. 9, p = 0. 022). Female sex and the wartime period independently predicted depression severity. Mean fear regarding clinic safety was 1. 9 +/- 1. 4 on a 7-point Likert scale and was higher in women, older and lymphoma patients. Thematic analysis revealed fear/anger about war and government (38%) as the most common difficulty, while family support (23%) was the main coping resource. Compared to the COVID-19 pandemic, the 2023-2025 war was associated with greater depression severity despite fewer care disruptions. Hematology services should incorporate systematic screening and psychosocial support to safeguard patient well-being during crises.
| Concepts | Keywords |
|---|---|
| Hematology | Coping |
| Israel | Depression |
| Psychosocial | Hematological malignancies |
| War | Mixed-methods |
| Survey | |
| War |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | hematological malignancies |
| disease | MESH | COVID-19 pandemic |
| disease | MESH | included |
| disease | MESH | CAR |
| disease | MESH | lymphoma |